SECTION 01 EVIDENCE INDEX
Six findings, at a glance
Each card represents a sourced claim from the bremelanotide literature. Hover any citation marker for the full reference.
Co-primary endpoints met at P<0.0001
Least-squares mean change vs placebo of +0.35 on FSFI-Desire and -0.33 on FSDS-DAO Item 13 over 24 weeks, both at P<0.0001 across the integrated 1,202-woman population.
Sustained efficacy, no new safety signals
Of the ~856 double-blind completers, 80% enrolled in the open-label extension. Drug-arm women gained an additional 1.25-1.30 FSFI-D points; crossover women gained 0.70-0.77.
Central mechanism confirmed
A single subcutaneous dose increased self-reported desire for up to 24 hours and modulated erotica-evoked brain activity — increased amygdala-insula connectivity, reduced cognitive-monitoring activity.
Tolerability profile, 18-month exposure
Across 43 completed studies: nausea 40.0% vs 1.3% placebo, flushing 20.3% vs 1.3%, headache 11.3% vs 1.9%, injection-site reactions 5.4% vs 0.5%. No treatment-related deaths.
Appetite suppression matched tirzepatide
Phase 2 BMT-801 reported 71% vs 73% improvement on a validated daily appetite questionnaire and substantially blunted appetite rebound after tirzepatide discontinuation.
Co-formulated with PDE5 inhibitor
Phase 2 trial launched June 2024 of a co-formulated bremelanotide + PDE5 inhibitor for ED patients who respond inadequately to PDE5i monotherapy; topline targeted 1H 2026.
Mechanism: a central agonist, not a peripheral vasodilator
Bremelanotide is a non-selective melanocortin-receptor agonist with its principal therapeutic activity at MC4R, the melanocortin-4 receptor [5][16]. MC4R is expressed densely in the hypothalamic medial preoptic area (mPOA) and the paraventricular nucleus — circuits that organize the appetitive, motivational component of sexual response.
The proposed model, supported by both rodent work and human imaging, runs roughly as follows. MC4R agonism on hypothalamic dopaminergic neurons (mPOA, ventral tegmental area, nucleus accumbens) increases dopamine release in mesolimbic reward circuitry [16]. Concurrent action on amygdala and cortico-limbic networks reduces the inhibitory cognitive monitoring that, in HSDD, appears to dampen erotic processing [5]. The net effect is restored appetitive drive, not enhanced peripheral arousal mechanics.
Thurston and colleagues confirmed this in a randomized, double-blind, crossover fMRI study of 31 premenopausal women with HSDD: a single subcutaneous dose of bremelanotide increased self-reported sexual desire for up to 24 hours and modulated erotica-evoked brain activity — increasing amygdala-insula functional connectivity and reducing activity in the parietal operculum / secondary somatosensory cortex, regions associated with self-monitoring [5]. This was the first objective neuroimaging evidence that the drug acts through the central pathway its developers had hypothesized.
The preclinical behavioral foundation came from Pfaus and colleagues in 2004: in ovariectomized Long-Evans female rats, subcutaneous PT-141 at 50-200 μg/kg selectively increased solicitational behaviors (hops, darts) without affecting lordosis, pacing, or locomotion — the cleanest possible animal-model signal for an appetitive rather than consummatory effect [6].
RECONNECT: the Phase 3 program
Approval rested on two identically-designed pivotal trials, Studies 301 and 302 (ClinicalTrials.gov NCT02333071 and NCT02338960), collectively known as RECONNECT. The integrated population of 1,202 premenopausal women with HSDD was randomized 1:1 to 1.75 mg subcutaneous bremelanotide as-needed or matching placebo over 24 weeks [1].
The co-primary endpoints were the FSFI-Desire domain (a five-point scale from the validated 19-item Female Sexual Function Index) and Item 13 of the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO Item 13), a single 0-4 item rating personal distress about low sexual desire. Drug produced a least-squares mean change vs placebo of +0.35 on FSFI-Desire and -0.33 on FSDS-DAO Item 13, both at P<0.0001 [1].
Prespecified subgroup analyses subsequently published by Simon and colleagues found the effect was consistent across virtually all subgroups defined by age, BMI, baseline testosterone quartile, relationship status, and HSDD duration [4]. The 2025 secondary-endpoint analysis extended the picture: FSFI arousal-domain scores improved 23-25% over baseline by week 4 (vs 5-10% on placebo) and orgasm-domain scores 16-21% (vs 0-9%), with both effects continuing to widen through week 24 [14].
Long-term safety and the 52-week extension
RECONNECT was followed by a 52-week open-label extension. Of the approximately 856 women who completed the 24-week double-blind phase, 684 (80%) enrolled in the extension and 272 completed it — a real-world adherence pattern that Simon and colleagues characterized as consistent with treatment satisfaction despite the high baseline rate of post-dose nausea [2][18].
No new safety signals appeared. The most common treatment-related adverse events in the extension were nausea (40.4%), flushing (20.6%), and headache (12.0%) — essentially identical to the double-blind phase. Women who had received drug during the blinded phase saw an additional 1.25-1.30 point improvement in FSFI-Desire during the extension; women who crossed over from placebo gained 0.70-0.77 points [2].
The broader development-program safety database (43 completed studies, ~3,500 subjects, up to 18 months of exposure) reinforced the pattern: nausea 40.0%, flushing 20.3%, headache 11.3%, injection-site reactions 5.4%, no treatment-related deaths, and few serious adverse events [3].
The cardiovascular signal and the dose cap
Two label-driving safety findings shape clinical use. The first is a small, transient pressor effect: approximately +3 mmHg systolic and +2 mmHg diastolic within two hours of dosing, peaking at roughly +6/+3 mmHg in clinical pharmacology studies and resolving within 8-12 hours, accompanied by a small heart-rate decrease [10]. This is the basis for the label's contraindication in uncontrolled hypertension or known cardiovascular disease and the recommendation against use in patients at high cardiovascular risk.
The second is focal hyperpigmentation: discrete darkening of skin, gums, or breasts reported in roughly 1% of bremelanotide-treated patients in Phase 3 and rising with more than eight doses per 28-day period [11]. This is mediated by MC1R activation on cutaneous melanocytes — a predictable consequence of non-selective melanocortin agonism — and may be incompletely reversible. It drives the label's maximum-eight-doses-per-month cap.
Nausea is the most common reason for discontinuation [3][12]. It begins within roughly one hour post-dose, lasts a median of about 2.4 hours, and is usually mild-to-moderate and self-limiting; antiemetics are not part of the labeled regimen.
Pharmacokinetics in one card
Following a 1.75 mg subcutaneous dose, bremelanotide reaches a mean Cmax of 77.1 ng/mL with a median Tmax of approximately 1.0 hour and a terminal half-life of approximately 2.7 hours (range 1.9-4.0 h) [9]. Bioavailability is essentially complete (~100%) by the subcutaneous route. Protein binding is 21%, mean clearance is 6.5 L/h, and volume of distribution is 25 L. Elimination is predominantly renal (~65%) with the remainder via feces (~23%) [9].
The short half-life is the pharmacologic rationale for as-needed (not chronic daily) dosing. Onset of pharmacologic effect typically occurs within 45-60 minutes of injection — the basis for the label's recommendation to dose at least 45 minutes before anticipated activity — and self-reported desire benefit has been measurable for up to 24 hours in fMRI studies [5].
Early development and the intranasal years
Bremelanotide did not begin as an HSDD drug. The original Diamond program in the early 2000s tested intranasal PT-141 in healthy males and men with mild-to-moderate erectile dysfunction, finding a dose-dependent, statistically significant pro-erectile response above a 7 mg threshold, with first erection typically within 30 minutes [7]. A follow-up crossover study showed that 7.5 mg intranasal PT-141 plus 25 mg oral sildenafil produced a greater erectile response than sildenafil alone in 19 men with sildenafil-responsive ED — the first demonstration that central (melanocortin) and peripheral (PDE5) mechanisms could add [8].
Development pivoted to subcutaneous administration after intranasal blood-pressure signals emerged at higher doses, and the indication shifted to HSDD on the basis of the desire-domain effects seen in early female-population studies [19]. The eventual 2019 approval rested on RECONNECT [1][19].
What is being studied now (2024-2025)
Three active programs sit alongside the approved HSDD indication.
First, obesity. Phase 1 trials in obese premenopausal women had shown bremelanotide produced roughly 1.3-1.7 kg greater weight loss than placebo over 16 days, driven by approximately 400 kcal/day reduced caloric intake — a modest MC4R-mediated appetite effect [13]. The 2025 Phase 2 BMT-801 trial reported that low-dose bremelanotide produced appetite-suppression scores comparable to tirzepatide (71% vs 73% improvement on a validated daily appetite questionnaire) and substantially blunted the appetite/weight rebound otherwise seen on tirzepatide discontinuation [17]. This supports development of bremelanotide as both a co-administered and a maintenance therapy alongside GLP-1 / GIP agonists.
Second, combination ED. In June 2024 the sponsor initiated a Phase 2 trial of co-formulated bremelanotide plus a PDE5 inhibitor for the roughly 30-40% of ED patients who respond inadequately to PDE5i monotherapy, with topline targeted for the first half of 2026 [19]. This is the regulatory descendant of the 2005 Diamond combination work [8].
Third, oncology. A 2024 in vitro study by Suzuki and colleagues found that bremelanotide at concentrations non-toxic to normal cells suppressed survivin expression and induced cell death in human glioblastoma cell lines; effects were blocked by melanocortin-receptor antagonists and reversed by forced survivin overexpression, identifying MC3R/MC4R as candidate oncology targets and bremelanotide as a chemosensitizer for temozolomide and osimertinib [15]. This work is preclinical and the clinical implications remain undetermined.
